Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Cattrini

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Lancet (London, England)|February 8, 2018
Atezolizumab and bladder cancer: facing a complex diseaseCarlo Cattrini, Francesco Boccardo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2018
Androgen-Deprivation Therapy Is More Than Palliation in Oligometastatic Prostate CancerCarlo Cattrini, Elisa Zanardi, Francesco Boccardo
Cancer Treatment and Research Communications|October 22, 2020
Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational studyCarlo Cattrini, Matteo Capaia, Francesco Boccardo, et al.
Frontiers in Public Health|January 4, 2021
Medical Liability in Cancer Care During COVID-19 Pandemic: Heroes or Guilty?Rosario Barranco, Carlo Messina, Alessandro Bonsignore, et al.
Therapeutic Advances in Urology|June 21, 2019
To switch or not to switch? A real-life experience using dexamethasone in combination with abirateroneElisa Zanardi, Davide Soldato, Maria Maddalena Latocca, et al.
European Journal of Clinical Investigation|December 31, 2020
Efficacy and safety of PD1/PDL1 blockade with platinum-based chemotherapy for extensive small cell lung cancer: A pooled analysis of randomized trialsCarlo Messina, Massimiliano Salati, Marco Messina, et al.
Anti-Cancer Drugs|July 30, 2019
Reduced dose of cabazitaxel in metastatic castration-resistant prostate cancer: from PROSELICA trial to the real life: A single institution experienceGiacomo Vallome, Carlo Cattrini, Carlo Messina, et al.
Cancers|August 23, 2020
Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with CancerCarlo Cattrini, Melissa Bersanelli, Maria Maddalena Latocca, et al.
Seminars in Oncology|November 10, 2020
Combination therapy in metastatic renal cell carcinoma: Back to the future?Luigi Cerbone, Carlo Cattrini, Giacomo Vallome, et al.
International Journal of Cancer|August 17, 2022
Comments on "Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)"Carlo Cattrini, Carlo Messina, Alessia Mennitto, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Lancet (London, England)|February 8, 2018
Atezolizumab and bladder cancer: facing a complex diseaseCarlo Cattrini, Francesco Boccardo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2018
Androgen-Deprivation Therapy Is More Than Palliation in Oligometastatic Prostate CancerCarlo Cattrini, Elisa Zanardi, Francesco Boccardo
Cancer Treatment and Research Communications|October 22, 2020
Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational studyCarlo Cattrini, Matteo Capaia, Francesco Boccardo, et al.
Frontiers in Public Health|January 4, 2021
Medical Liability in Cancer Care During COVID-19 Pandemic: Heroes or Guilty?Rosario Barranco, Carlo Messina, Alessandro Bonsignore, et al.
Therapeutic Advances in Urology|June 21, 2019
To switch or not to switch? A real-life experience using dexamethasone in combination with abirateroneElisa Zanardi, Davide Soldato, Maria Maddalena Latocca, et al.
European Journal of Clinical Investigation|December 31, 2020
Efficacy and safety of PD1/PDL1 blockade with platinum-based chemotherapy for extensive small cell lung cancer: A pooled analysis of randomized trialsCarlo Messina, Massimiliano Salati, Marco Messina, et al.
Anti-Cancer Drugs|July 30, 2019
Reduced dose of cabazitaxel in metastatic castration-resistant prostate cancer: from PROSELICA trial to the real life: A single institution experienceGiacomo Vallome, Carlo Cattrini, Carlo Messina, et al.
Cancers|August 23, 2020
Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with CancerCarlo Cattrini, Melissa Bersanelli, Maria Maddalena Latocca, et al.
Seminars in Oncology|November 10, 2020
Combination therapy in metastatic renal cell carcinoma: Back to the future?Luigi Cerbone, Carlo Cattrini, Giacomo Vallome, et al.
International Journal of Cancer|August 17, 2022
Comments on "Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)"Carlo Cattrini, Carlo Messina, Alessia Mennitto, et al.
Pageof 6